Literature DB >> 12869409

Soy and isoflavone consumption in relation to prostate cancer risk in China.

Marion M Lee1, Scarlett Lin Gomez, Jeffrey S Chang, Mercy Wey, Run-Tian Wang, Ann W Hsing.   

Abstract

This case-control study in China evaluated the effect of soy food consumption and isoflavones (genistein and daidzein) on the risk of prostate cancer. One hundred and thirty-three cases and 265 age- and residential community-matched controls between the ages of 50 and 89 years were interviewed in person between 1989 and 1992. Usual consumption of soy foods and isoflavones was assessed using a food frequency questionnaire developed in China and a nutrient database developed and validated in Asian-American populations. The age- and total calorie-adjusted odds ratio (OR) of prostate cancer risk comparing the highest tertile of tofu intake to the lowest tertile was 0.58 [95% confidence interval (CI), 0.35-0.96]. There were also statistically significant associations comparing the highest quartile of intake of soy foods (OR, 0.51; 95% CI, 0.28-0.95) and genistein (OR, 0.53; 95% CI, 0.29-0.97) with the lowest quartiles. There was also an indication of a reduced risk associated with intake of daidzein (OR, 0.56; 95% CI, 0.31-1.04 for the highest versus lowest quartile). Our results indicate a reduced risk of prostate cancer associated with consumption of soy foods and isoflavones. These findings should be confirmed in longitudinal follow-up studies in populations with varying risk of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869409

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  52 in total

Review 1.  Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Subhash Padhye
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 2.  The role of estrogens and estrogen receptors in normal prostate growth and disease.

Authors:  Gail S Prins; Kenneth S Korach
Journal:  Steroids       Date:  2007-11-12       Impact factor: 2.668

Review 3.  Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  Cancer Treat Rev       Date:  2009-08-05       Impact factor: 12.111

4.  Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin.

Authors:  Tze-Chen Hsieh; Joseph M Wu
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

Review 5.  Estrogens and prostate cancer: etiology, mediators, prevention, and management.

Authors:  Shuk-Mei Ho; Ming-Tsung Lee; Hung-Ming Lam; Yuet-Kin Leung
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-07       Impact factor: 4.741

6.  LC-ESI-MS based characterisation of isoflavones in soybean (Glycine max (L.) Merr.) from India.

Authors:  M K Akitha Devi; S Sravan Kumar; P Giridhar
Journal:  J Food Sci Technol       Date:  2018-09-29       Impact factor: 2.701

Review 7.  Cellular signaling perturbation by natural products.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong
Journal:  Cell Signal       Date:  2009-03-16       Impact factor: 4.315

Review 8.  Notch inhibitors for cancer treatment.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

9.  Urinary phytoestrogen excretion and prostate cancer risk: a nested case-control study in the Multiethnic Cohort.

Authors:  S-Y Park; L R Wilkens; A A Franke; L Le Marchand; K K Kakazu; M T Goodman; S P Murphy; B E Henderson; L N Kolonel
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

10.  Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.

Authors:  Young Kwang Chae; Han-Yao Huang; Paul Strickland; Sandra C Hoffman; Kathy Helzlsouer
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.